TABLE 4.
Cardiometabolic risk and erythropoietic blood markers
| Cardiometabolic risk blood markers | Baseline | 8 weeks |
|---|---|---|
| Glucose (mg/dl) | 101.8 ± 28.5 | 96.4 ± 18.4 |
| Insulin (μIU/ml) | 10.3 ± 6.7 | 10.4 ± 9.5 |
| HOMA‐IR (%) | 1.5 ± 0.8 | 1.4 ± 1.1 |
| Total cholesterol (mg/dl) | 166.1 ± 45.9 | 161.4 ± 49.2 |
| HDL‐C (mg/dl) | 39.0 ± 9.3 | 43.8 ± 9.9* |
| LDL‐C (mg/dl) | 82.6 ± 49.9 | 89.2 ± 45.6 |
| Triglycerides (mg/dl) | 222.8 ± 160.3 | 142.4 ± 62 |
| Erythropoietic blood markers | ||
|---|---|---|
| EPO (mIU/ml) | 14.31 ± 8.0 | 20.43 ± 14.6 |
| Iron (mg/dl) | 108.4 ± 29.6 | 120.7 ± 38.1 |
| Ferritin (mg/dl) | 89.3 ± 64.9 | 112.5 ± 90.1 |
| Transferrin (mg/dl) | 305.1 ± 30.0 | 302.9 ± 25.8 |
All values are presented as means ± SD. Comparisons were made using paired t‐test or Wilcoxon matched‐pairs signed rank test.
*
P < 0.05 vs. baseline. Abbreviations: EPO, erythropoietin; HDL‐C, high‐density lipoprotein cholesterol; HOMA‐IR, homeostatic model assessment for insulin resistance; LDL‐C, low‐density lipoprotein cholesterol.